Statement Of Cash Flows [Abstract]

ABIVAX - Filing #2810976

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for interest expense
24 827 EUR
7 028 EUR
3 561 EUR
Cash flows from (used in) operations before changes in working capital
118 395 EUR
51 933 EUR
44 381 EUR
Increase (decrease) in working capital
21 265 EUR
2 002 EUR
667,000 EUR
Adjustments for decrease (increase) in trade and other receivables
14 231 EUR
312,000 EUR
1 977 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income other than contract liabilities
81,000 EUR
26,000 EUR
41,000 EUR
Adjustments for increase (decrease) in employee benefit liabilities
109,000 EUR
143,000 EUR
117,000 EUR
Adjustments for impairment loss recognised in profit or loss, goodwill
EUR
13 632 EUR
EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from sale or issue of treasury shares
10,000 EUR
143,000 EUR
EUR
Proceeds from exercise of warrants
3,000 EUR
3,000 EUR
EUR
Payments for share issue costs
28 111 EUR
3 280 EUR
4 153 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.